Licensed use — if any
No authorised wound-healing, recovery or sports indication is established. FDA reviewed nominated TB-500 bulk substances for wound-healing compounding in 2026.
Preview openPlanned full launch in
--Days--Hrs--Min--Sec
← Peptide Intelligence
Experimental peptide fragment
TB-500
Thymosin beta-4 fragment (LKKTETQ)
A short synthetic fragment associated with thymosin beta-4 marketing. Evidence for full thymosin beta-4 should not be treated as evidence for TB-500.
Research interest
Preclinical tissue repair, cell migration and wound-healing questions, with frequent online extrapolation beyond the evidence.
Evidence lens
Known does not mean proven for everything.
The strongest claim on the page should never be stronger than the strongest source behind it.
- TB-500 is not interchangeable with full-length thymosin beta-4.
- FDA reported that it had not identified human exposure data for the TB-500 fragment in its safety review.
- WADA has funded detection research and prohibits TB-500 in tested sport.
- Clinical effectiveness for injury recovery.
- Human pharmacokinetics and long-term safety.
- Manufacturing consistency of online products.
- FDA highlights possible immunogenicity, aggregation and peptide-related impurities.
- The absence of clinical exposure data prevents a reliable human risk estimate.
- Use in tested sport creates a clear anti-doping issue.
Regulatory snapshot
Jurisdiction and context matter.
Not presented as a UK-authorised medicine. The substance, claims and intended supply need specialist review.
Not FDA approved; subject to current FDA compounding safety review.
TB-500 is prohibited by WADA. Athletes should not treat 'research use' wording as protection.
Primary sources
Open the record.
Statuses change. Always check the current regulator, product label, trial record and anti-doping list.
Do not start, stop or source a medicine based on this page. Speak to a qualified healthcare professional and use regulated supply routes. Call 999 in an emergency or NHS 111 for urgent advice.
Continue through the library →